Johnson & Johnson products on a shelf in a store in New York.
Lucas Jackson | Reuters
Johnson & Johnson’s consumer health business Kenvue priced its IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion.
At that IPO price, the new company will be valued at around $41 billion. That makes Kenvue’s debut one of the largest U.S. IPOs in more than a year.
related investing news
The company expected to price 151 million shares between $20 and $23 per share, according to a preliminary prospectus it filed with the Securities and Exchange Commission last week.
Proceeds from the offering and any profits from related debt-financing transactions will go to J&J, but Kenvue will retain $1.17 billion in cash and cash equivalents.
Goldman Sachs, JPMorgan Chase and Bank of America are acting as the lead underwriters for the IPO.
Shares will begin trading Friday on New York Stock Exchange under the ticker “KVUE.”
The…
2023-05-03 19:36:30
Link from www.cnbc.com